MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$594,105K
International
$12,823K
Product
$606,928K
(93.46%↑ Y/Y)
License
$9,359K
Revenue
$616,287K
(87.32%↑ Y/Y)
Operating income
$123,324K
(194.13%↑ Y/Y)
Total costs and
expenses
$492,963K
Income tax benefit
(expense)
-$339,789K
(-15468.11%↓ Y/Y)
Net income before
taxes
$107,390K
(319.59%↑ Y/Y)
Total other expense
-$15,934K
(2.45%↑ Y/Y)
Other income
$10,793K
(40.30%↑ Y/Y)
Total selling,
general and...
$232,034K
(50.38%↑ Y/Y)
Total research and
development
$160,215K
(69.92%↑ Y/Y)
Cost of revenue
$100,714K
(161.69%↑ Y/Y)
Net income
$447,179K
(1812.41%↑ Y/Y)
Interest expense
$26,727K
(11.23%↑ Y/Y)
Other selling,
general and...
$183,981K
(49.68%↑ Y/Y)
Noncash compensation
$48,053K
(53.13%↑ Y/Y)
Other research and
development
$143,597K
(72.74%↑ Y/Y)
Noncash compensation
$16,618K
(48.91%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)